Lymphocytopenia - Pipeline Insight, 2024

This “Lymphocytopenia- Pipeline Insight, 2024,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Lymphocytopenia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Lymphocytopenia Understanding

Lymphocytopenia: Overview

Lymphocytopenia is an abnormally low number of lymphocytes (a type of white blood cell) in the blood. Various disorders and conditions, including infection with viruses such as human immunodeficiency virus (HIV) - the virus that causes AIDS - the influenza virus, SARS-CoV-2 can decrease the number of lymphocytes in the blood. Lymphocytopenia can be Acute: Occurring briefly during certain conditions and then usually resolving and Chronic: Occurring for a longer period because of long-lasting disorders. The number of lymphocytes can remain low for a long time when people have: Undernutrition, certain autoimmune disorders, such as systemic lupus erythematosus (lupus), rheumatoid arthritis, and myasthenia gravis, certain chronic infections, such as AIDS and miliary tuberculosis or certain cancers, such as leukemias and lymphomas. The number of lymphocytes may be very low permanently in certain hereditary immunodeficiency disorders such as Di George syndrome, Wiskott-Aldrich syndrome, severe combined immunodeficiency, and ataxia-telangiectasia. Mild lymphocytopenia may cause no symptoms. Sometimes, symptoms of the condition that caused lymphocytopenia may be present. For example, people may have enlarged lymph nodes and an enlarged spleen, suggesting cancer or HIV infection, cough, runny nose, and fever, suggesting a respiratory viral infection and small tonsils or lymph nodes, suggesting an inherited immune system disorder. Mild lymphocytopenia is usually diagnosed by chance when a complete blood count is done for other reasons. Complete blood count testing also is done in people with recurrent or severe infections and in people with infections caused by organisms that do not usually cause infections. Such testing may show severe lymphocytopenia as an explanation for why the person has developed recurrent or unusual infections. Treatment of lymphocytopenia depends mainly on the cause. Lymphocytopenia caused by a drug usually begins to resolve within days after a person stops taking the drug. If the lymphocytopenia is the result of AIDS, combination therapy with at least three antiviral drugs of different classes can increase the number of T cells and lengthensurvival.

Lymphocytopenia- Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Lymphocytopenia pipeline landscape is provided which includes the disease overview and Lymphocytopenia treatment guidelines. The assessment part of the report embraces, in depth Lymphocytopenia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Lymphocytopenia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Lymphocytopenia R&D. The therapies under development are focused on novel approaches to treat/improve Lymphocytopenia.

Lymphocytopenia Emerging Drugs Chapters

This segment of the Lymphocytopenia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Lymphocytopenia Emerging Drugs

GX-I7: Genexine GX-I7 is a long-acting human IL-7 which is essential for homeostatic T cell proliferation and improves lymphopenia, typically induced by chemotherapy or radiation therapy. The safety has been proved via phase I clinical trial in healthy volunteers and phase I b and I b/II Clinical trials are being conducted to evaluate the safety, tolerability, pharmacokinetics/pharmacodynamics and efficacy. Currently the drug is in Preclinical stage of clinical trial evaluation for the treatment of Idiopathic CD4lymphocytopenia.

Lymphocytopenia: Therapeutic Assessment

This segment of the report provides insights about the different Lymphocytopenia drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Lymphocytopenia

There are approx. 5+ key companies which are developing the therapies for Lymphocytopenia. The companies which have their Lymphocytopenia drug candidates in the most advanced stage, i.e. Preclinical include, Genexine.

Phases

This report covers around 5+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Lymphocytopenia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Molecule Type

Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Lymphocytopenia: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Lymphocytopenia therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Lymphocytopenia drugs.

Lymphocytopenia Report Insights

• Lymphocytopenia Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Lymphocytopenia Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Lymphocytopenia drugs?
• How many Lymphocytopenia drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Lymphocytopenia?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Lymphocytopenia therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Lymphocytopenia and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Genexine
• Neo ImmuneTech
• Apogenix
• I-MAB Biopharma

Key Products

• GX-I7
• NT-I7